血管内皮生长因子与卡瑞利珠单抗治疗晚期非鳞非小细胞肺癌所致反应性毛细血管增生症的相关性

betway必威登陆网址 (betway.com )学报››2024,Vol. 45››Issue (3): 135-138.DOI:10.3969/j.issn.2097-0005.2024.03.002

• 临床研究 •上一篇

血管内皮生长因子与卡瑞利珠单抗治疗晚期非鳞非小细胞肺癌所致反应性毛细血管增生症的相关性

何杨¹, 陶绍能², 张丽琴³()

^1.皖南医学院第一附属医院，肿瘤内科
^2.核医学科
^3.呼吸内科，安徽芜湖 241001

收稿日期:2023-04-19出版日期:2024-03-25发布日期:2024-04-16
通讯作者:张丽琴
基金资助:
安徽省高等学校自然betway必威亚洲项目(2022AH051237)

Correlation between vascular endothelial growth factor and reactive cutaneous capillary endothelial proliferation of advanced non-squamous non-small cell lung cancer patients treated with camrelizumab

Yang HE¹, Shaoneng TAO², Liqin ZHANG³()

^1.Department of Medical Oncology, The First Affiliated Hospital of Wannan Medical College，Wuhu 241001，China
^2.Department of Medical Nuclear, The First Affiliated Hospital of Wannan Medical College，Wuhu 241001，China
^3.Department of Medical Respiratory, The First Affiliated Hospital of Wannan Medical College，Wuhu 241001，China

Received:2023-04-19Online:2024-03-25Published:2024-04-16
Contact:Liqin ZHANG

摘要/Abstract

摘要：

目的探讨血管内皮生长因子（vascular endothelial growth factor，VEGF）对卡瑞利珠单抗（又称SHR‑1210）治疗晚期非鳞非小细胞肺癌（non‑squamous non‑small cell lung cancer，nsNSCLC）所致反应性毛细血管增生症（reactive cutaneous capillary endothelial proliferation，RCCEP）的预测作用以及两者间的相关性。方法回顾性分析我院经卡瑞利珠单抗治疗并检测VEGF的64例晚期nsNSCLC患者。将治疗后发生RCCEP的46例患者纳入A组，未发生RCCEP的18例患者纳入B组，对比两组的治疗效果及VEGF正常率，分析VEGF对RCCEP发生的预测作用，以及两者之间的相关性。结果A组和B组的客观缓解率（objective response rate，ORR）、疾病控制率（disease control rate，DCR）差异无统计学意义（P> 0.05）；A组VEGF高于正常值的患者明显多于B组，差异有统计学意义（P< 0.001）；VEGF数值预测RCCEP发生的ROC曲线下面积为0.908，预测的灵敏度为80.4%，特异度为83.3%，误诊率为16.7%，漏诊率为19.6%，约登指数为63.7%；VEGF水平和RCCEP分级之间呈正相关（r_s = 0.806，P< 0.001）。结论卡瑞利珠治疗后发生RCCEP的患者中VEGF高于正常值的发生率较多，VEGF水平对发生RCCEP有一定的预测性，其灵敏度和特异度较高，且RCCEP分级随着VEGF数值增加而升高。

关键词:反应性毛细血管增生症,血管内皮生长因子,卡瑞利珠单抗,非鳞非小细胞肺癌

Abstract:

ObjectiveTo investigate the predictive effect of the vascular endothelial growth factor （VEGF） in circulating blood on reactive cutaneous capillary endothelial proliferation （RCCEP） induced by camrelizumab treatment in patients with advanced non-squamous non-small cell lung cancer.MethodsA retrospective analysis was conducted on 64 patients with advanced nsNSCLC who were treated with camrelizumab （SHR-1210） and tested for VEGF in the First Affiliated Hospital of Wannan Medical College. Forty-six patients who experienced RCCEP after treatment were divided into Group A， and 18 patients that did not experience RCCEP were divided into Group B. The treatment efficiency and the normal rate of VEGF were compared between the two groups. Moreover， the predictive effect of VEGF on the occurrence of RCCEP， and the correlation between the level of VEGF and the grade of RCCEP were analyzed.ResultsBoth ORR and DCR in Group A were higher than those in Group B， but the difference was not statistically significant （P> 0.05）. The number of patients with abnormal VEGF values in Group A was significantly larger than that in Group B （P< 0.001）. The AUC of the numerical prediction of VEGF for RCCEP was 0.908. The sensitivity was 80.4%， and the specificity was 83.3%. The misdiagnosis rate was 16.7%， the missed diagnosis rate was 19.6%， and the Youden index was 63.7%. VEGF level and RCCEP grade showed a positive correlation （r_s = 0.806，P< 0.001）.ConclusionThe incidence of abnormal VEGF values in patients with RCCEP caused by the treatment of camrelizumab is higher. The level of VEGF has a predictive effect on the occurrence of RCCEP， and its sensitivity and specificity are high. And the RCCEP grade increases with the increase of VEGF value.

Key words:reactive cutaneous capillary endothelial proliferation,vascular endothelial growth factor,camrelizumab,non-squamous non-small cell lung cancer

何杨, 陶绍能, 张丽琴. 血管内皮生长因子与卡瑞利珠单抗治疗晚期非鳞非小细胞肺癌所致反应性毛细血管增生症的相关性[J]. betway必威登陆网址 (betway.com )学报, 2024, 45(3): 135-138.

Yang HE, Shaoneng TAO, Liqin ZHANG. Correlation between vascular endothelial growth factor and reactive cutaneous capillary endothelial proliferation of advanced non-squamous non-small cell lung cancer patients treated with camrelizumab[J]. Journal of ShanDong First Medical University&ShanDong Academy of Medical Sciences, 2024, 45(3): 135-138.

图/表2

图1VEGF数值预测RCCEP的ROC曲线VEGF为血管内皮生长因子；RCCEP为反应性毛细血管增生症。

表2RCCEP分级和VEGF的相关性分析

RCCEP 分级	VEGF				合计	r _s	P
RCCEP 分级	≤ N	> N ~ 2N	> 2N ~ 3N	> 3N	合计	r _s	P
1	9	7	2	0	18	0.806	< 0.001
2	0	16	9	0	25
3	0	0	0	3	3
合计	9	23	11	3	46

表2RCCEP分级和VEGF的相关性分析

RCCEP 分级	VEGF				合计	r _s	P
RCCEP 分级	≤ N	> N ~ 2N	> 2N ~ 3N	> 3N	合计	r _s	P
1	9	7	2	0	18	0.806	< 0.001
2	0	16	9	0	25
3	0	0	0	3	3
合计	9	23	11	3	46

参考文献21

1	McNutt M. Cancer immunotherapy［J］.Science，2013，342（6165）： 1417.
2	Darnell EP， Mooradian MJ， Baruch EN， et al. Immune-related adverse events （irAEs）： diagnosis， management， and clinical pearls［J］.Curr Oncol Rep，2020，22（4）： 39.
3	Markham A， Keam SJ. Camrelizumab： first global approval［J］.Drugs，2019，79（12）： 1355.
4	Chen X， Ma L， Wang X， et al. Reactive capillary hemangiomas： a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210［J］.Cancer Biol Med，2019，16（1）： 173.
5	Apte RS， Chen DS， Ferrara N. VEGF in signaling and disease： beyond discovery and development［J］.Cell，2019，176（6）： 1248.
6	Elebiyo TC， Rotimi D， Evbuomwan IO， et al. Reassessing vascular endothelial growth factor （VEGF） in anti-angiogenic cancer therapy［J］.Cancer Treat Res Commun，2022，32： 100620.
7	中国临床肿瘤学会抗肿瘤药物安全管理专家委员会，中国临床肿瘤学会免疫治疗专家委员会. 卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识［J］.临床肿瘤学杂志，2020，25（9）： 840.
8	Han Y， Liu D， Li L. PD-1/PD-L1 pathway： current researches in cancer［J］.Am J Cancer Res，2020，10（3）： 727.
9	Peng Z， Wei J， Wang F， et al. Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma［J］.Clin Cancer Res，2021，27（11）： 3069.
10	Huang J， Xu J， Chen Y， et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma （ESCORT）： a multicentre， randomised， open-label， phase 3 study［J］.Lancet Oncol，2020，21（6）： 832.
11	Wang F， Qin S， Sun X， et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab： data derived from a multicenter phase 2 trial［J］.J Hematol Oncol，2020，13（1）： 47.
12	Hwang SJ， Carlos G， Wakade D， et al. Cutaneous adverse events （AEs） of anti-programmed cell death （PD）-1 therapy in patients with metastatic melanoma： a single-institution cohort［J］.J Am Acad Dermatol，2016，74（3）： 455.
13	Kumar V， Gabrilovich DI. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment［J］.Immunology，2014，143（4）： 512.
14	Multhoff G， Vaupel P. Hypoxia compromises anti-cancer immune responses［J］.Adv Exp Med Biol，2020，1232： 131.
15	Dvorak HF. Reconciling VEGF with VPF： the importance of increased vascular permeability for stroma formation in tumors， healing wounds， and chronic inflammation［J］.Front Cell Dev Biol，2021，9： 660609.
16	Cheng K， Liu CF， Rao GW. Anti-angiogenic agents： a review on vascular endothelial growth factor receptor-2 （VEGFR-2） inhibitors［J］.Curr Med Chem，2021，28（13）： 2540.
17	Sabat R， Wolk K， Loyal L， et al. T cell pathology in skin inflammation［J］.Semin Immunopathol，2019，41（3）： 359.
18	Khalil S， Bardawil T， Kurban M， et al. Tissue-resident memory T cells in the skin［J］.Inflamm Res，2020，69（3）： 245.
19	Bhardwaj M， Chiu MN， Pilkhwal Sah S. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors： pathogenesis， treatment， and surveillance［J］.Cutan Ocul Toxicol，2022，41（1）： 73.
20	Vogel M， Bachmann MF. Immunogenicity and immunodominance in antibody responses［J］.Curr Top Microbiol Immunol，2020，428： 89.
21	Li W， Wei Z， Yang X， et al. Salvage therapy of reactive capillary hemangiomas： Apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer［J］.J Cancer Res Ther，2019，15（7）： 1624.

[1]	张美燕.沙利度胺预防及治疗卡瑞利珠单抗致反应性皮肤毛细血管增生症的效果[J]. betway必威登陆网址（betway.com ）学报, 2022, 43(8): 584-587.
[2]	李腾宇, 张霞, 于肖鹏, 李晓光, 王西冉, 王延秀, 刘焕燕.口腔鳞癌Survivin表达及其在血管生成中的作用[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(9): 667-669.